| Rank |
Status |
Study |
| 1 |
Unknown †
|
ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors
| Conditions: |
Upper Gastrointestinal Submucosal Tumors (SMTs); Gastrointestinal Stromal Tumors (GISTs); Leiomyoma |
| Interventions: |
Procedure: ESTD; Procedure: VATS |
| Outcome Measures: |
En bloc resection; Curative resection; Procedure related complication; Short-term morbidity; Local recurrence; Quality of life |
|
| 2 |
Recruiting
|
Evaluation of People With Gastrointestinal Disease
| Condition: |
Gastrointestinal Diseases |
| Intervention: |
|
| Outcome Measures: |
Evaluate patients with Gastrointestinal disorders.; During a clinically indicated standard of care test or procedure, allow for donation of extra stool, urine, blood, gastric aspirate or Gastrointestinal tissue sample for collection and storage.; Allow outpatient evaluation and follow-up of patients with a variety of Gastrointestinal diseases for the purposes of physician education in the NIDDK accredited gastroenterology training program. |
|
| 3 |
Recruiting
|
Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients
| Conditions: |
Gastrointestinal Bleeding; Complication of Internal Device |
| Intervention: |
|
| Outcome Measures: |
Proportion of VAD Patients with Gastrointestinal Bleeding as Assessed by HemoQuant Fecal Occult Blood Testing; Examine Behavior of Gastrointestinal Bleeding in VAD Patients By Estimating the Proportion of VAD Patients with an Abnormal HemoQuant Test Prior to Implantation |
|
| 4 |
Recruiting
|
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
| Conditions: |
Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer of the Gastrointestinal Tract; Gastrointestinal Cancer; Neoplasms, Gastrointestinal |
| Intervention: |
|
| Outcome Measure: |
|
|
| 5 |
Recruiting
|
EUS-FNA Versus KHB in Diagnostics of Upper Gastrointestinal Submucosal Tumors
| Condition: |
Other Specified Disorders of Esophagus, Stomach or Duodenum |
| Interventions: |
Procedure: Key Hole Biopsy ( KHB); Procedure: EUS-FNA |
| Outcome Measures: |
To compare the yield and success of KHB and EUS-FNA in cytological / histological and immunohistochemical diagnostics of Upper Gastrointestinal Submucosal Tumors.; Detection of mitotic activity in case of Gastrointestinal Stromal Tumors |
|
| 6 |
Not yet recruiting
|
An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract
| Conditions: |
C.Surgical Procedure; Digestive System; Symptomatic Disorders of the Gastrointestinal Tract; Gastric Anastomosis (Site); Gastrointestinal Neoplasms |
| Intervention: |
Device: Monosyn |
| Outcome Measures: |
Frequency of anastomosis leakage rate; Postoperative complication rate; Reoperation rate; Length of hospital stay; Stay in the intensive care unit; Duration to perform the anastomosis; Cost; Handling of the device |
|
| 7 |
Not yet recruiting
|
Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
| Condition: |
Relapsing-Remitting Multiple Sclerosis |
| Intervention: |
Drug: BG00012 |
| Outcome Measures: |
Incidence Of Gastrointestinal-Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period; Severity Of Gastrointestinal -Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period; Duration Of Gastrointestinal -Related Events In Participants Who Utilize Symptomatic Therapy During The 12-Week Treatment Period; Percentage Of Participants Requiring Gastrointestinal Symptomatic Therapy During The 12-Week Treatment Period; Number of Participants Who Used Symptomatic Therapies for Gastrointestinal -Related Events During the 12-Week Treatment Period; Duration of Use of Symptomatic Therapies for Gastrointestinal -Related Events During the 12-Week Treatment Period; Kaplan-Meier Estimates for the Proportion of Participants Who Require BG00012 Dose Reduction In Response To Gastrointestinal -Related Events; The Percentage of Participants Who Discontinue BG00012 Due To Gastrointestinal -Related Events |
|
| 8 |
Recruiting
|
Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders
| Conditions: |
Functional Gastrointestinal Disorders (FGID); FGID According to the Rome III Criteria; Irritable Bowel Syndrome (IBS); Functional Abdominal Pain; Functional Dyspepsia |
| Intervention: |
Other: Cognitive behavior therapy |
| Outcome Measures: |
Change in Faces Pain Rating Scale (FACES) from baseline to 10 weeks; Change in Faces Pain Rating Scale (FACES) from baseline to 8 months.; Change in Gastrointestinal Symptom Rating Scale (GSRS-IBS) from baseline to 10 weeks.; Change in Children´s Somatization Inventory (CSI 24) from baseline to 10 weeks; Change in Gastrointestinal Symptom Scale (PedsQL Gastro) from baseline to 10 weeks; Change in Functional Disability Index (FDI) from baseline to 10 weeks.; Change in Pain Reactivity Scale from baseline to 10 weeks.; Change in IBS-behavioral responses questionnaires (IBS-BRQ) from baseline to 10 weeks.; Change in Spence Children Anxiety Scale (SCAS) from baseline to 10 weeks.; Change in Child Depression Inventory (CDI) from baseline to 10 weeks.; Change in Pain Interference Index (PII) from baseline to 10 weeks.; Change in Pediatric Quality of Life Inventory (Peds QL) from baseline to 10 weeks.; Change in Gastrointestinal Symptom Rating Scale (GSRS-IBS) from baseline to 8 months.; Change in Children´s Somatization Inventory (CSI 24) from baseline to 8 months; Change in Gastrointestinal Symptom Scale (PedsQL Gastro) from baseline to 8 months.; Change in Functional Disability Index (FDI) from baseline to 8 months.; Change in IBS-behavioral responses questionnaires (IBS-BRQ) from baseline to 8 months.; Change in Spence Children Anxiety Scale (SCAS) from baseline to 8 months.; Change in Child Depression Inventory (CDI) from baseline to 8 months.; Change in Pain Interference Index (PII) from baseline to 8 months.; Change in Pediatric Quality of Life Inventory (Peds QL) from baseline to 8 months.; Change in Pain Reactivity Scale from baseline to 8 months. |
|
| 9 |
Unknown †
|
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
| Conditions: |
Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer |
| Interventions: |
Other: questionnaire administration; Procedure: Gastrointestinal complications management/prevention; Procedure: quality-of-life assessment |
| Outcome Measures: |
Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire; Physician assessment of adverse effects using LENT SOMA scales of radiation injury; Patient self-assessments using EORTC QLQ-C30 and Defecation Problem Subscale of QLQ-CR38; Photographic images of rectal mucosa; Physician assessment of rectal dysfunction based on the modified CTCAE grading system; Health economics data |
|
| 10 |
Recruiting
|
Development of Early Detection Signs for Gastrointestinal Cancer
| Condition: |
GI Cancer |
| Intervention: |
Other: Specimen bank |
| Outcome Measures: |
The first goal of this proposal is to collect cells from the peripheral blood, tumor draining lymph nodes and tumor infiltrating lymphocytes in patients with early or late stage Gastrointestinal cancers.; The second goal is to evaluate using novel proteomic, CellomicTM, and genomic techniques the serum and peripheral blood lymphocytes of these patients for protein, cellular changes and genetic markers that correlate with the presence of cancer. |
|
| 11 |
Recruiting
|
A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders
| Conditions: |
Autism; Gastrointestinal Symptoms |
| Interventions: |
Other: GFCF product with GFCF diet; Other: product containing gluten and casein (milk protein) with GFCF diet |
| Outcome Measure: |
A study to assess the role of a gluten free-casein free diet in the dietary management of autism associated Gastrointestinal disorders |
|
| 12 |
Recruiting
|
Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients
| Condition: |
Gastrointestinal Neoplasms |
| Intervention: |
Behavioral: Education/Daily Planning |
| Outcome Measures: |
Percentage of patients with diagnosed Gastrointestinal cancer who showed daily compliance using activity monitors and tablet computers to measure physical activity.; Percentage of patients with a diagnosis of Gastrointestinal cancer that benefit from an intervention of physical activity daily planning and education. |
|
| 13 |
Not yet recruiting
|
Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
| Condition: |
Advanced Gastrointestinal Stromal Tumors |
| Intervention: |
Drug: PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively. |
| Outcome Measures: |
Efficacy assessment of PD-0332991; Objective response; Progression-free survival; Overall survival; Progression; Safety of PD-0332991 |
|
| 14 |
Recruiting
|
Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding
| Conditions: |
Gastrointestinal Bleeding; Cirrhosis |
| Intervention: |
Drug: Ornithine-phenylacetate |
| Outcome Measures: |
Ammonia plasma concentration umol/L.; Hepatic encephalopathy |
|
| 15 |
Recruiting
|
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
| Condition: |
Gastrointestinal Adenocarcinomas |
| Intervention: |
Drug: MEDI-565 |
| Outcome Measures: |
Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI-565 in subjects with Gastrointestinal (GI) adenocarcinomas for which no standard or curative treatments are available.; Evaluate the safety profile in adult subjects with advanced Gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.; Assess the safety and antitumor activity of MEDI-565 in the dose-expansion phase.; Pharmacokinetics of MEDI-565; Immunogenicity of MED-565 |
|
| 16 |
Recruiting
|
ELIGIBLE (Efficacy of Left atrIal Appendage Closure After Gastrointestinal BLEeding)
| Condition: |
Adverse Reaction to Drugs Affecting the Gastrointestinal System |
| Intervention: |
Device: Left atrial appendage occlusion |
| Outcome Measure: |
Combined overall mortality, major bleeding, stroke or procedure-related complications |
|
| 17 |
Recruiting
|
Adverse Events During Upper Gastrointestinal Endoscopy
| Conditions: |
Patients Need Upper Gastrointestinal Endoscopy; Peptic Ulcer; Gastric Cancer; Esophagus Cancer; Oesophagitis |
| Intervention: |
|
| Outcome Measure: |
Adverse events |
|
| 18 |
Recruiting
|
The Impact of Rockall Risk Scoring System on Management of Upper Gastrointestinal System Bleeding
| Condition: |
Gastrointestinal Hemorrhage |
| Intervention: |
Procedure: Gastroscopy |
| Outcome Measures: |
The necessity of emergency endoscopy.; Morbidity; Mortality; Length of hospital stay |
|
| 19 |
Not yet recruiting
|
The Use of Hexacapron in Upper Gastrointestinal Bleeding
| Conditions: |
Upper Gastrointestinal Bleeding; Hexacapron; Hemostasis; Rebleeding; Mortality |
| Interventions: |
Drug: Hexacapron( Tranexamic acid); Drug: esomeprazole |
| Outcome Measures: |
Prevention of rebleeding manifested as hematemesis, melena and drop in hemoglobin level by 2g% within 24 hours after therapeutic endoscopy; Rebleeding, need for surgery , 30 day mortality |
|
| 20 |
Recruiting
|
Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding
| Conditions: |
Gastrointestinal Hemorrhage; Hematemesis |
| Interventions: |
Drug: Erythromycin; Procedure: gastric lavage |
| Outcome Measures: |
Visual quality of endoscopy; need for a second-look endoscopy; need of blood transfusion; number of adverse events as a measure of safety and tolerability; length of hospitalisation; length of endoscopic procedure; need for arteriography or surgery |
|
